Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 8/20 | 0.47 |
| ▸ | PDE6D | O43924 | 1/20 | 0.47 |
| ▸ | PDE6A | P16499 | 1/20 | 0.47 |
| ▸ | PDE6G | P18545 | 1/20 | 0.47 |
| ▸ | PDE6B | P35913 | 1/20 | 0.47 |
| ▸ | PDE6C | P51160 | 1/20 | 0.47 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653298 | 0.90 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDTDP1KMT2A | |
| SCHEMBL14653182 | 0.89 | MRGPRX4 (0.53) | PDE5A | |
| SCHEMBL16116525 | 0.86 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDTDP1KMT2A | |
| Methane SCHEMBL15732492 | 0.85 | PDE5A (0.47) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6620528 | 0.83 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDTDP1KMT2A | |
| SCHEMBL31694381 | 0.83 | PDE5A (0.59) | ALDH1A1MAPTHPGDPDE5APDE6D | |
| SCHEMBL1679801 | 0.83 | PDE5A (0.59) | ALDH1A1MAPTHPGDPDE5APDE6D | |
| SCHEMBL29972749 | 0.83 | PDE5A (0.59) | ALDH1A1MAPTHPGDPDE5APDE6D | |
| SCHEMBL14653206 | 0.83 | PDE5A (0.46) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL15732445 | 0.82 | MAPT (0.41) | ALDH1A1MAPTTDP1KMT2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735567-B1 | HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND | XUANZHU PHARMA CO LTD (CN) | 2016-10-26 | — | — | EP | disclosed |
| US-8980904-B2 | Heterocyclic substituted pyrimidine compound | Xuanzhu Pharma Co., Ltd. (CN) | 2015-03-17 | — | — | US | disclosed |
| US-8980904-B2 | Heterocyclic substituted pyrimidine compound | Xuanzhu Pharma Co., Ltd. (CN) | 2015-03-17 | — | — | US | disclosed |
| US-20140288063-A1 | Heterocyclic Substituted Pyrimidine Compound | Xuanzhu Pharma Co., Ltd. (CN) | 2014-09-25 | — | — | US | disclosed |
| US-20140288063-A1 | Heterocyclic Substituted Pyrimidine Compound | Xuanzhu Pharma Co., Ltd. (CN) | 2014-09-25 | — | — | US | disclosed |
| EP-2735567-A1 | HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010382-A1 | HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND | 山东亨利医药科技有限责任公司 (CN) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288063-A1 | Heterocyclic Substituted Pyrimidine Compound | PDE3B, PDE5A, PDE3A | ALDH1A1 1423/4885MAPT 4084/4885HPGD 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.